Post-exposure intradermal antirabies vaccine: a cheaper alternative for developing countries.

Area of Science:

• Vaccinology
• Infectious Disease Epidemiology
• Public Health

Background:

• Rabies remains a significant public health concern, particularly in developing regions.
• Traditional post-exposure prophylaxis (PEP) methods, such as nervous tissue vaccines, have limitations in safety and efficacy.
• Human diploid-cell vaccine (HDCV) offers a potential alternative for rabies prevention.

Purpose of the Study:

• To evaluate the safety and efficacy of intradermal (i.d.) administration of human diploid-cell vaccine (HDCV) for post-exposure rabies treatment.
• To assess antibody formation and long-term outcomes in patients receiving i.d. HDCV.
• To compare the cost-effectiveness and suitability of i.d. HDCV for widespread use in resource-limited settings.

Main Methods:

• A retrospective study analyzing data from a rural mission hospital in central Thailand from 1979 onwards.
• Administration of four 0.1 ml doses of i.d. HDCV over a two-week period.
• Monitoring for significant side effects, assessment of antibody formation, and follow-up for rabies cases for one year.

Main Results:

• Consistent and significant antibody formation was observed in all patients.
• No significant adverse side effects were reported during the treatment period.
• No cases of rabies were observed in patients followed up for one year post-vaccination.

Conclusions:

• Intradermal (i.d.) HDCV is a safe and effective vaccine for post-exposure rabies treatment.
• This vaccination strategy demonstrates superior safety and efficacy compared to older nervous tissue vaccines.
• The moderate cost and proven effectiveness of i.d. HDCV support its wider implementation in the Third World for rabies prevention.